The plasma fractionation market is expected to reach USD 50.1 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.8 percent from its 2023-e valuation of USD 31.7 billion. Convalescent plasma became more and more in demand during the COVID-19 pandemic, especially since physicians first used it to treat virus-affected patients. The extensive use of convalescent plasma to treat hospitalized COVID-19 patients and stop the disease’s progression was highlighted in a June 2021 article published in Frontiers. Research showed that convalescent plasma transfusions improved viral clearance and symptomatology, which raised the initial demand for plasma fractions to treat COVID-19 patients. The market under study is anticipated to grow steadily over the course of the forecast period as the pandemic slows down and fewer infections occur.

The market is expected to grow due to the expanding use of immunoglobulins in a variety of therapeutic areas, the aging population and the rise in rare disease prevalence, as well as the expansion of plasma collection facilities globally. According to WHO data from October 2022, the number of people in the world who are 60 and older is predicted to almost double by 2050, with 80 percent of them living in low- and middle-income nations. Due to the fast aging of this population, rare diseases are expected to increase globally, which will increase the use of plasma fractionation products and fuel market expansion.

Health Technology Insights: Medrio Enhances RTSM For Faster Clinical Trial Starts and Greater Flexibility

Furthermore, the rising geriatric population, coupled with the escalating burden of rare diseases such as Von Willebrand’s disease affecting approximately 1% of the global population, is expected to drive demand for plasma fractionation products, fostering market growth.

The coagulation factors segment, also known as coagulation factor concentrates, experienced growth in 2023 due to advancements in hemostasis technology, leading to the introduction of a diverse range of products to aid clinicians in providing adequate assistance to hemophilic patients. The growth is further fueled by an increase in accidents and trauma cases. A PubMed Central published article indicates that the mortality rate among severely injured trauma patients with coagulation complications is 3 to 4 times higher than those without such complications.

Health Technology Insights: Resilience and JobsOhio Announce Continued Partnership and Expansion in Blue Ash

The pulmonology sector is anticipated to witness significant growth during the forecast period 2024-2030. This growth is attributed to the increasing utilization of Intravenous Immunoglobulin (IVIG) in the management of various pulmonary diseases. IVIG is used in pulmonology to treat autoimmune lung diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD). By modulating the immune system, IVIG can potentially reduce inflammation and improve lung function.

Plasma Fractionation Market Press Release

The plasma fractionation market is characterized by the presence of various small and big players. The major market players include ADMA Biologics, Bharat Serum Vaccines, CSL, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Japan Blood Products, Kamada, Kedrion, LFB, Octapharma, Prothya Biosolutions, Sanquin, SK Plasma, Takeda Pharmaceutical amongst others.  

In a competitive market landscape, players are swiftly embracing advanced technologies to enhance the plasma fractionation market and bolster their competitive stance through strategic initiatives, including mergers, acquisitions, and introducing new products. For instance, in September 2022, Kedrion Biopharma and Bio Products Laboratory joined forces to establish a global entity specializing in medicinal products derived from human blood plasma. This collaboration aims to address the needs of patients facing rare and life-threatening conditions, enhancing their access to vital treatments.

TRENDING REPORTS

Health Technology Insights: Healthcare.com Launches Autopilot: AI-Driven Enrollment Platform

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

About  Intent Market Research™

Intent Market Research (IMR) is a market research firm dedicated to providing unique, data-driven insights that support sustainable and inclusive business growth. We specialize in comprehensive market research reports and consulting services across diverse industries including chemicals, healthcare, automotive, energy, packaging, and semiconductor & electronics.

Our approach centers on delivering transformative market intelligence through syndicated reports, custom research, and strategic consulting services. We work closely with clients to develop tailored solutions that address unique business challenges, offering quantifiable market insights and forward-looking strategies. Our team of expert analysts and consultants combines cutting-edge competencies with a robust research methodology to help businesses explore new markets, develop innovative products, and uncover growth opportunities.

At IMR, we are committed to ethical standards and compliance, conducting research with transparency and integrity. We prioritize data privacy, maintain strict confidentiality, and adhere to industry regulations. Our goal is to empower businesses with comprehensive, fact-based insights that drive sustainable advantages and meaningful organizational change.

To find out more, visit Intent Market Research™ or follow us on LinkedIn. 

Contact:
Mr. Jay Kumar
Intent Market Research

1846 E Innovation Park DR Site
100 ORO Valley
AZ 85755

USA: +1 463-583-2713
Email: sales@intentmarketsearch.com